Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 9/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 9/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 9/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8044313 | 0.92 | PRSS1 (0.41) | PRSS1PRSS2PRSS3ALDH1A1SMN1; SMN2 | |
| SCHEMBL8042785 | 0.90 | PRSS1 (0.41) | PRSS1PRSS2PRSS3ALDH1A1SMN1; SMN2 | |
| SCHEMBL2109694 | 0.88 | PRSS1 (0.47) | APPPRSS1PRSS2PRSS3MAOA | |
| SCHEMBL2109697 | 0.88 | PRSS1 (0.47) | APPPRSS1PRSS2PRSS3MAOA | |
| SCHEMBL2110635 | 0.79 | PRSS1 (0.51) | PRSS1PRSS2PRSS3MAOAMAOB | |
| SCHEMBL2110631 | 0.79 | PRSS1 (0.51) | PRSS1PRSS2PRSS3MAOAMAOB | |
| SCHEMBL2109988 | 0.78 | PRSS1 (0.49) | PRSS1PRSS2PRSS3MAOAMAOB | |
| SCHEMBL2109993 | 0.78 | PRSS1 (0.49) | PRSS1PRSS2PRSS3MAOAMAOB | |
| SCHEMBL8046395 | 0.78 | PRSS1 (0.46) | PRSS1PRSS2PRSS3MAOAMAOB | |
| SCHEMBL2108237 | 0.77 | PRSS1 (0.56) | PRSS1PRSS2PRSS3MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536189-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-8536189-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | COSTANZO MICHAEL J (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | COSTANZO MICHAEL J (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2009067202-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | APP 2189/4885PRSS1 7/4885PRSS2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.